In this review, we discuss the underlying molecular mechanisms of PARP and PARP inhibitors and the results from the clinical studies that investigated the effects of the FDA-approved PARP inhibitors on epithelial ovarian cancers. The gene discussed is PARP1; the disease is ovarian carcinoma.